← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
PSUS
Pershing Square USA, Ltd.
Valuation N/A
Unknown
Price$38.49
Model IV—
P/IV—
Limited data — see page
PTA
Cohen & Steers Tax-Advantaged Preferred Securities & Income Fund
Valuation N/A
Unknown
Price$17.81
Model IV—
P/IV—
Limited data — see page
PTGX
Protagonist Therapeutics, Inc
Valuation N/A
Healthcare Risk 42 · Elevated
Price$148.18
Model IV—
P/IV—
Market implies +35.8%/yr vs model +13.9% · above model
PTLE
PTL Ltd
Valuation N/A
Consumer Defensive Risk 53 · Elevated
Price$7.72
Model IV—
P/IV—
Market implies +29.4%/yr vs model +2.0% · above model
PTN
PALATIN TECHNOLOGIES INC
Valuation N/A
Healthcare Risk 39 · Moderate
Price$10.94
Model IV—
P/IV—
Market implies -6.8%/yr vs model +15.0% · below model
PTNM
Pitanium Ltd
Valuation N/A
Consumer Defensive Risk 35 · Moderate
Price$10.39
Model IV—
P/IV—
Market implies +21.9%/yr vs model +15.0% · above model
PTOR
Praetorian Acquisition Corp.
Valuation N/A
Financial Services
Price$9.99
Model IV—
P/IV—
Limited data — see page
PTORU
Praetorian Acquisition Corp.
Valuation N/A
Financial Services
Price$10.15
Model IV—
P/IV—
Limited data — see page
PTORW
Praetorian Acquisition Corp.
Valuation N/A
Financial Services
Price$0.35
Model IV—
P/IV—
Limited data — see page
PTY
PIMCO CORPORATE & INCOME OPPORTUNITY FUND
Valuation N/A
Unknown
Price$11.43
Model IV—
P/IV—
Limited data — see page
PUK
PRUDENTIAL PLC
Valuation N/A
Financial Services Risk 33 · Moderate
Price$26.68
Model IV—
P/IV—
Limited data — see page
PULM
Pulmatrix, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$1.41
Model IV—
P/IV—
Market implies -11.2%/yr vs model +15.0% · below model
PURR
Hyperliquid Strategies Inc
Valuation N/A
Financial Services Risk 40 · Elevated
Price$11.85
Model IV—
P/IV—
Limited data — see page
PUSA
Aureus Greenway Holdings Inc
Valuation N/A
Communication Services Risk 55 · Elevated
Price$3.66
Model IV—
P/IV—
Market implies +76.4%/yr vs model +2.0% · above model
PVL
Permianville Royalty Trust
Valuation N/A
Energy
Price$1.87
Model IV—
P/IV—
Limited data — see page
PVLA
PALVELLA THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$150.13
Model IV—
P/IV—
Market implies +53.5%/yr vs model +15.0% · above model
PWP
Perella Weinberg Partners
Valuation N/A
Financial Services Risk 31 · Moderate
Price$14.79
Model IV—
P/IV—
Market implies +28.3%/yr vs model +2.0% · above model
PWRL
Powerlaw Corp.
Valuation N/A
Unknown
Price$10.26
Model IV—
P/IV—
Limited data — see page
PXED
Phoenix Education Partners, Inc.
Valuation N/A
Consumer Defensive Risk 58 · Elevated
Price$26.84
Model IV—
P/IV—
Limited data — see page
PXLW
PIXELWORKS, INC
Valuation N/A
Technology Risk 41 · Elevated
Price$7.14
Model IV—
P/IV—
Market implies +85.7%/yr vs model +2.0% · above model
PYPD
PolyPid Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$5.33
Model IV—
P/IV—
Limited data — see page
PYT
PPLUS Trust Series GSC-2
Valuation N/A
Financial Services
Price$23.77
Model IV—
P/IV—
Limited data — see page
PYXS
Pyxis Oncology, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$3.21
Model IV—
P/IV—
Market implies +38.4%/yr vs model +15.0% · above model
PZG
Paramount Gold Nevada Corp.
Valuation N/A
Basic Materials Risk 31 · Moderate
Price$1.32
Model IV—
P/IV—
Market implies +32.6%/yr vs model +5.0% · above model
QADR
QDRO Acquisition Corp.
Valuation N/A
Financial Services
Price$9.98
Model IV—
P/IV—
Limited data — see page
QADRU
QDRO Acquisition Corp.
Valuation N/A
Financial Services
Price$10.10
Model IV—
P/IV—
Limited data — see page
QADRW
QDRO Acquisition Corp.
Valuation N/A
Financial Services
Price$0.25
Model IV—
P/IV—
Limited data — see page
QBTS
D-Wave Quantum Inc.
Valuation N/A
Technology Risk 46 · Elevated
Price$16.83
Model IV—
P/IV—
Market implies +79.2%/yr vs model +40.7% · above model
QCLS
Q/C TECHNOLOGIES, INC.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$1.71
Model IV—
P/IV—
Limited data — see page
QETA
Quetta Acquisition Corp
Valuation N/A
Financial Services Risk 28 · Moderate
Price$11.85
Model IV—
P/IV—
Limited data — see page
QETAR
Quetta Acquisition Corp
Valuation N/A
Financial Services Risk 37 · Moderate
Price$0.41
Model IV—
P/IV—
Limited data — see page
QETAU
Quetta Acquisition Corp
Valuation N/A
Financial Services Risk 44 · Elevated
Price$11.51
Model IV—
P/IV—
Limited data — see page
QMMM
QMMM Holdings Ltd
Valuation N/A
Technology Risk 45 · Elevated
Price$119.40
Model IV—
P/IV—
Market implies +113.5%/yr vs model +2.0% · above model
QNC
Quantum eMotion Corp
Valuation N/A
Technology Risk 50 · Elevated
Price$1.70
Model IV—
P/IV—
Limited data — see page
QNCX
Quince Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$29.55
Model IV—
P/IV—
Limited data — see page
QNRX
Quoin Pharmaceuticals, Ltd.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$6.79
Model IV—
P/IV—
Limited data — see page
QNTM
Quantum Biopharma Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$3.20
Model IV—
P/IV—
Limited data — see page
QQQX
Nuveen NASDAQ 100 Dynamic Overwrite Fund
Valuation N/A
Unknown
Price$30.37
Model IV—
P/IV—
Limited data — see page
QRED
QuasarEdge Acquisition Corp
Valuation N/A
Financial Services Risk 58 · Elevated
Price$10.04
Model IV—
P/IV—
Limited data — see page
QS
QuantumScape Corp
Valuation N/A
Technology Risk 39 · Moderate
Price$5.05
Model IV—
P/IV—
Limited data — see page
QSEA
Quartzsea Acquisition Corp
Valuation N/A
Financial Services Risk 27 · Moderate
Price$10.64
Model IV—
P/IV—
Limited data — see page
QSEAR
Quartzsea Acquisition Corp
Valuation N/A
Financial Services Risk 33 · Moderate
Price$0.15
Model IV—
P/IV—
Limited data — see page
QSEAU
Quartzsea Acquisition Corp
Valuation N/A
Financial Services Risk 32 · Moderate
Price$10.98
Model IV—
P/IV—
Limited data — see page
QSI
Quantum-Si Inc
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.74
Model IV—
P/IV—
Market implies +74.6%/yr vs model +15.0% · above model
QTEX
QTREX Quantum Ltd.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.89
Model IV—
P/IV—
Market implies +77.0%/yr vs model +15.0% · above model
QUCY
Quantum Cyber N.V.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$1.34
Model IV—
P/IV—
Market implies +60.5%/yr vs model +15.0% · above model
QUIK
QUICKLOGIC Corp
Valuation N/A
Technology Risk 44 · Elevated
Price$10.82
Model IV—
P/IV—
Market implies +65.9%/yr vs model +2.8% · above model
QULL
UBS AG
Valuation N/A
Financial Services Risk 33 · Moderate
Price$70.67
Model IV—
P/IV—
Limited data — see page
QUMS
Quantumsphere Acquisition Corp
Valuation N/A
Financial Services Risk 51 · Elevated
Price$10.34
Model IV—
P/IV—
Limited data — see page
QUMSR
Quantumsphere Acquisition Corp
Valuation N/A
Financial Services Risk 54 · Elevated
Price$0.06
Model IV—
P/IV—
Limited data — see page
QUMSU
Quantumsphere Acquisition Corp
Valuation N/A
Financial Services Risk 42 · Elevated
Price$10.38
Model IV—
P/IV—
Limited data — see page
QURE
uniQure N.V.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$43.10
Model IV—
P/IV—
Market implies +65.5%/yr vs model +2.0% · above model
QXL
QUANTUM X LABS INC.
Valuation N/A
Technology Risk 55 · Elevated
Price$4.44
Model IV—
P/IV—
Market implies -7.0%/yr vs model +15.0% · below model
QXO
QXO, Inc.
Valuation N/A
Industrials Risk 45 · Elevated
Price$12.11
Model IV—
P/IV—
Market implies +111.9%/yr vs model +6.0% · above model
RA
Brookfield Real Assets Income Fund Inc.
Valuation N/A
Unknown
Price$12.18
Model IV—
P/IV—
Limited data — see page
RAAQ
Real Asset Acquisition Corp.
Valuation N/A
Financial Services
Price$13.42
Model IV—
P/IV—
Limited data — see page
RAAQU
Real Asset Acquisition Corp.
Valuation N/A
Financial Services
Price$13.00
Model IV—
P/IV—
Limited data — see page
RAAQW
Real Asset Acquisition Corp.
Valuation N/A
Financial Services
Price$5.10
Model IV—
P/IV—
Limited data — see page
RAC
Rithm Acquisition Corp.
Valuation N/A
Financial Services
Price$10.58
Model IV—
P/IV—
Limited data — see page
RACC
Research Alliance Corp III
Valuation N/A
Financial Services Risk 47 · Elevated
Price$11.30
Model IV—
P/IV—
Limited data — see page